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Summary Background Genetic abnormalities in cell cycle
control are common in malignant melanoma. UCN-01 (7-
hydroxystaurosporine) is an investigational agent that
exhibits antitumor activity by perturbing the cancer cell
cycle. A patient with advanced melanoma experienced a
partial response in a phase I trial of single agent UCN-01.
We sought to determine the activity of UCN-01 against
refractory metastatic melanoma in a phase II study. Patients
and methods Patients with advanced melanoma received
UCN-01 at 90 mg/m
2 over 3 h on cycle 1, reduced to
45 mg/m
2 over 3 h for subsequent cycles, every 21 days.
Primary endpoint was tumor response. Secondary endpoints
included progression-free survival (PFS) and overall sur-
vival (OS). A two-stage (17+16), single arm phase II
design was employed. A true response rate of ≥20% (i.e., at
least one responder in the first stage, or at least four
responders overall) was to be considered promising for
further development of UCN-01 in this setting. Results
Seventeen patients were accrued in the first stage. One
patient was inevaluable for response. Four (24%) patients
had stable disease, and 12 (71%) had disease progression.
As there were no responders in the first stage, the study was
closed to further accrual. Median PFS was 1.3 months (95%
CI, 1.2–3.0) while median OS was 7.3 months (95% CI, 3.4–
18.4). One-year and two year OS rates were 41% and 12%,
respectively. A median of two cycles were delivered (range,
1–18). Grade 3 treatment-related toxicities include hypergly-
cemia (N=2), fatigue (N=1), and diarrhea (N=1). One
patient experienced grade 4 creatinine elevation and grade
4 anemia possibly due to UCN-01. No dose modification
was required as these patients had disease progression.
Conclusion Although well tolerated, UCN-01 as a single
agent did not have sufficient clinical activity to warrant
further study in refractory melanoma.
Keywords Metastatic melanoma.UCN-01.
7-hydroxystaurosporine.Cell cycle inhibitor.Phase II.
Targeted therapy
Introduction
Melanoma is the sixth most common cancer in the United
States, and the number of melanoma cases diagnosed
annually is increasing faster than for any other cancer [1].
The management of patients with metastatic melanoma is a
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patients with metastatic disease is approximately 6 months
and less than 10% of patients will survive 5 years [1, 2].
Despite the commercial availability of numerous agents to
treat melanoma, standard therapy for this malignancy today
is considered experimental (www.nccn.org). Treatment
approaches have traditionally included cytotoxic chemo-
therapy and immunotherapy, used either alone or in
combination [3–6]. However, these approaches have not
improved outcomes in this disease, with the recent
exception of the anti-CTLA4 agent ipilimumab [7]. Thus,
there is an unmet need to develop more effective
approaches for the treatment of metastatic melanoma.
Genetic abnormalities in cell cycle regulation, particu-
larly G1-S checkpoint control, are common in melanoma
[8]. Regulation of G1 phase control consists of inhibition of
cyclin-dependent kinases (CDKs) and upreguation of CDK
inhibitors, with subsequent hypophosphorylation of the
retinoblastoma (Rb) tumor suppressor protein. Particularly,
disruption of the CDK inhibitors p21
waf1/cip1 (hereafter,
p21) and p27
kip1 (hereafter, p21), and inactivation of tumor
suppressor genes CDKN2A (a single gene that encodes two
tumor suppressor proteins p16
INK4A and p19
ARF)o r
retinoblastoma (Rb), have been reported in metastatic
melanoma [9]. Recent studies demonstrated that p16
protein loss was found in 50% of patients with familial
melanomas [10] and was associated with high proliferative
activity (as measured by Ki-67 staining) [11]. New agents
targeting these cell cycle regulatory mechanisms may be
useful in the treatment of melanoma.
UCN-01 (7-hydroxystaurosporine), a derivative of the
serine/threonine kinase inhibitor staurosporine, was origi-
nally isolated from the culture broth of Streptomyces
species as a protein kinase C-selective inhibitor [12]. While
UCN-01 is a potent inhibitor of certain PKC isoenzymes
[13], the precise mechanism of action for its antitumor
activity is still not fully understood. Many clinical studies
support the observation that UCN-01 causes arrest of cell
cycle progression at G1/S phase and/or abrogation of arrest
at G2 phase at concentrations that reduce PKC activity [14–
16], although the extent to which PKC inhibition contrib-
utes to these effects remains unknown. In addition, UCN-01
exerts its anticancer activity by induction of apoptosis and
sensitization to DNA-damaging agents [17, 18]. Several
phase I studies of UCN-01 either as monotherapy or in
combination with cytotoxic agents have been reported [19–
26]. One partial response lasting 8 months was reported in a
patient with refractory metastatic melanoma enrolled in a
single agent phase I trial of UCN-01 [20]. UCN-01
administered as a 3-h infusion every 3 weeks led to higher
dose intensity (mg/m
2/h) and less toxicity compared to a
72-h infusion in a phase I study in patients with advanced
solid tumors [19]. The primary objective of this single-arm
phase II study was to assess the anti-tumor activity of
UCN-01 monotherapy as determined by the response rate in
metastatic melanoma with intended correlative target
validation.
Patients and methods
Eligibility
Patients were required to have histologically or cytologi-
cally confirmed diagnosis of melanoma that was incurable
by other means such as surgery, radiotherapy or limb
perfusion. Patients were required to have none or one prior
chemotherapy regimen and/or two or less biological
therapies for metastatic disease. At least 4 weeks must
have elapsed since prior therapy (6 weeks for nitrosoureas
or mitomycin C) and the patient must have recovered from
all toxicities attributable to prior therapy. Additional key
inclusion criteria included: at least one measurable lesion
by Response Evaluation Criteria in Solid Tumors (RECIST)
[27], age ≥18 years, life expectancy of greater than
4 months, Eastern Cooperative Oncology Group (ECOG)
performance status of 0–2; and adequate end-organ func-
tion. Patients with known brain metastases were eligible
only if disease was controlled and patient was asymptom-
atic and not receiving corticosteroids.
This trial was reviewed, approved, and sponsored by the
Cancer Therapy Evaluation Program of the National Cancer
Institute (ClinicalTrials.gov, identifier NCT00072189) un-
der a contract (N01 CM17101) with the California Cancer
Consortium. The local institutional review board at each
participating institution approved the protocol. All patients
gave written, informed consent.
Treatment protocol
UCN-01 was provided to the NCI under a Clinical Trials
Agreement (CTA) between Kyowa Hakko Kogyo Company,
Ltd. and the NCI Division of Cancer Treatment and
Diagnosis. UCN-01 was given at 90 mg/m
2 over 3 h on
cycle 1, reduced to 45 mg/m
2 over 3 h for subsequent cycles.
One cycle was defined as 21 days.
Evaluation of response and toxicity
All patients underwent computed tomography (CT) of the
chest and abdomen within 4 weeks of registration. Tumor
response was assessed every 3 weeks by clinical examina-
tion and every two cycles by CT using RECIST. Toxicity
was graded according to the National Cancer Institute
Common Terminology Criteria for Adverse Events, version
2.0. For patients who experienced grade 3–4 toxicity, the
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resumed in the next cycle with a one-dose level reduction
(to 36 mg/m
2 for the first reduction and to 27 mg/m
2 for the
second reduction).
Statistical considerations
A two-stage design was used in this study, with response
rate as the primary efficacy endpoint. Secondary end-
points included overall survival (OS), progression-free
survival (PFS), and toxicity. Pharmacodynamic correlates
were planned to evaluate whether target inhibition (i.e.,
disruption of G1 phase progression) was achievable. All
eligible patients were included in the efficacy analysis,
and all treated patients were included in the safety
analysis. The study assumed that a true response rate
>20% would warrant further study of this regimen, while
a true response rate of <5% would not warrant further
study. Using this design, the probability of correctly
declaring that an agent with a true response rate of 20%
warranted further study was 0.91 (power). The probabil-
ity of declaring that an agent with only a 5% true
response rate warranted further study was 0.08 (alpha).
In the first stage of accrual, 17 evaluable patients were to
be enrolled and assessed. If no response was observed,
then accrual would stop, with the conclusion that the
regimen was not promising for further study in these
patients. If one or more responses were seen in the first
17 patients, an additional 16 patients would be accrued
in the second stage. Four or more responses out of 33
would be considered evidence that the regimen warrants
further study, provided that other factors such as toxicity
and survival also appeared favorable. PFS was defined as
the time from registration until disease progression or
death without documented progression disease. OS was
defined as the time from registration until death. Patients
who died without documentation of progression were
considered to have progressed on the date of their death.
The time to event distributions were estimated using the
Kaplan-Meier method. All p-values were two-sided with
statistical significance evaluated at the 0.05 alpha level.
Correlative studies
It was hypothesized that the efficacy of UCN-01 in
melanoma would be dependent on the status of specific
G1-phase cell cycle regulators. Further, it was hypothesized
that UCN-01 activity could be seen in surrogate tissues
(specifically buccal mucosal cells) and that melanoma
response to UCN-01 could be monitored through surrogate
markers in patient plasma, specifically secreted IL-6 or shed
tumor methylated p16 DNA. It was thought that patients
with tumors having low p27 expression, low Ki-67
expression, loss of RB, hypermethylation of the p16
promotor, would be less responsive to UCN-01. Figure 1
illustrates the schema for correlative studies.
Immunohistochemical(IHC)staining Pretreatment formalin-
fixed, paraffin-embedded (FFPE) diagnostic specimens
were obtained and analyzed for the expression of the
expression of p27, Ki-67, RB and pRB by routine IHC.
The commercially available antibodies included: RB
(antibody clone mAB245, Chemicon International, Inc.);
phosphorylated-RB (sc-7986 goat polyclonal; Santa Cruz
Biotechnology); underphosphorylated-Rb (antibody clone
mAB549; Chemicon International, Inc.); p27
Kip1 (antibody
clone DCS72; Oncogene Science); Ki-67 (Mib1 antibody;
AMAC, Westbrook, ME). Both percentage of positive cells
(from 1% to 100%) and intensity of staining (from 0 to 3+)
were scored using the positive control tissues as 3+. Total
score was established by multiplying the percentage by
intensity, giving scores of 0–300. Final scores of 0, 1, 2,
and 3 were given for total scores of 0, 1–50, 50–100, and
100–300, respectively. For p27, tumors staining positive in
less than 40% of cells were scored as abnormal for p27.
Buccal mucosal cells Surrogate epithelial cells from buccal
brushings were obtained from selected patients prior to
Fig. 1 Schema of the study
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of UCN-01 treatment. Buccal mucosa was scraped with a
brush and then transferred to a slide. Slides were fixed with
4% paraformaldehyde solution for 20 min then stored in
70% ethanol. These specimens were analyzed for p27
expression by IHC as described above, using beta-actin
expression as internal control.
Tumor DNA and protein in plasma Blood draws at pre-
treatment and at the start of the second and third cycles of
UCN-01 treatment were obtained for analyses of plasma
proteinsandshedtumor DNA.Bloodsamples wereprocessed
within2hafterdrawing.PlasmawereassayedforlevelsofIL-6
using a commercially available ELISA kit (R&D Systems,
Minneapolis, MN). The methylation status of p16 promoter
were determined using the CpG WIZ™ Amplification Kit
assay (Intergen Co. Purchase, NY), which was a two-part assay
that detects unmethylated p16 promoter in one tube and any
methylated p16 promoter in another reaction.
(A) Progression-Free Survival (PFS) 
(B)  Overall Survival (OS) 
Fig. 2 Kaplan-Meier curves of progression-free survival (A) and
overall survival (B) in all 17 patients
Table 1 Baseline demographics and clinical characteristics of study
patients
Baseline characteristics No. %
Patients evaluable/enrolled 16/17 94
Gender: Female % 11 65
Age at enrollment, years
Median 53
Range 34–85
Race/Ethnicity
White 13 76
Hispanic 3 18
Asian 1 6
ECOG performance status
01 0 5 9
16 3 5
21 6
Primary malignant melanoma
Skin 14 82
Esophagus 1 6
Peritonium 1 6
Unknown 1 6
Primary histology
Malignant melanoma, NOS 13 76
Nodular melanoma 3 18
Malignant melanoma in junction nevus 1 6
Sites of metastatic disease
M1a: skin, subcutaneous or lymph nodes 4 24
M1b: lung 13 76
M1c: distant organs 14 82
No. of metastatic sites
13 1 8
24 2 4
35 2 9
>3 5 29
Prior adjuvant/Neoadjuvant therapy
Surgery 17 100
Radiation 3 18
Immunotherapy (alpha interferon) 5 29
Prior metastatic therapy
Surgery 0 0
Radiation 0 0
Chemotherapy/Molecularly targeted agents 15 88
Chemotherapy
07 4 1
16 3 6
24 2 4
Molecularly targeted agents
08 4 8
19 5 4
Immunotherapy 9 53
Vaccine 1 6
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Adverse event Grades 1 or 2 Grade 3 Grade 4 Any grade
(N=17) No. of patients % No. of patients % No. of patients % No. of patients %
Hematologic
Anemia 6 35 1 6 7 41
Neutropenia 3 18 3 18
Lymphopenia 1 6 1 6
Thrombocytopenia 1 6 1 6
Gastrointestinal
Nausea 9 53 9 53
Vomiting 5 29 5 29
Diarrhea 2 12 1 6 3 18
Dehydration 1 6 1 6
Constipation 1 6 1 6
Abdominal pain* 1 6 1 6
Constitutional
Fatigue 5 29 1 6 6 35
Anorexia 2 12 2 12
Fever 1 6 1 6
Metabolic
Hyperglycemia 9 53 2 12 11 65
Hypomagnesemia 2 12 2 12
Hypermagnesemia 1 6 1 6
Hyponatremia 3 18 3 18
Hypocalcemia 3 18 3 18
Hypokalemia 2 12 2 12
Hypophosphatemia 1 6 1 6
Hypoalbuminemia 3 18 3 18
ALT, SGPT 2 12 2 12
AST, SGOT 2 12 2 12
Hyperbilirubinemia 1 6 1 6
Hypercholesteremia 2 12 2 12
Hypertriglyceridemia 2 12 2 12
Hyperuricemia 1 6 1 6
Neurologic
Pain 4 24 4 24
Neuropathy, sensory 2 12 2 12
Dizziness 1 6 1 6
Somnolence 1 6 1 6
Renal
Creatinine 1 6 1 6 2 12
Musculoskeletal
Musculoskeletal disorder 1 6 1 6
Cardiovascular
Supraventricular and nodal arrhythmia 1 6 1 6
Skin
Rash/desquamation 2 12 2 12
Patient #11 had severe abdominal pain shortly after starting the treatment, and was off the study as “unlikely” related to treatment.
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Patient characteristics
Between 11/04/2003 and 12/13/2004, seventeen eligible
patients were accrued to the first stage of the study. Further
accrual was terminated after no responses were seen in this
initial cohort. Table 1 summarizes the baseline demographic
and clinical characteristics of these patients.
Efficacy
Of the 17 patients, one patient was inevaluable for response
due to early withdrawal after acute abdominal pain deemed
unlikely related to treatment. No objective response was
observed. Four (24%) patients had stable disease after more
than two cycles of treatment, and 12 (71%) patients had
disease progression. All 16 evaluable patients had disease
progression before death. Median PFS was 1.3 months (95%
CI, 1.2–3.0; range 0.7–9.5 months). Sixteen of the 17 eligible
patients had died at the time of this report. The follow-up time
for the early withdrawal patient, who had been subsequently
treated with temozolomide, was over 5 years at the time of
data cut-off on March 25, 2010. The median OS was
7.3 months (95% CI, 3.4–18.4; range 2.4–61.8 months).
One-year survival rate was 41% and two-year survival rate
was 12%. Figure 2 shows the Kaplan-Meier curves of PFS
and OS for all 17 patients.
Treatment administered and adverse effects
A total of 54 cycles of treatment was given to the 17
eligible patients, with a median number of two cycles (rang,
1–18). Table 2 summarizes the possibly, probably, or
definitely treatment-related adverse events in all 17 patients
who received at least one dose of treatment. The most
common toxicities included hyperglycemia (N=11, 65%),
nausea (N=9, 53%), anemia (N=7, 41%), fatigue (N=6,
35%), vomiting (N=5, 29%), and pain (N=4, 24%). Grade
3 treatment-related toxicities include hyperglycemia (N=2),
fatigue (N=1), and diarrhea (N=1) and one patient
experienced grade 4 creatinine elevation and grade 4
anemia possibly due to UCN-01. No dose modifications
were required as these patients had disease progression.
Correlative studies
Only pretreatment tumor specimens were collected,
including 20 blood specimens and ten tumor biopsies
that were performed 72 h after initiation of UCN-01
treatment (seven patients) and 16 buccal mucosa samples
(six patients). Ten pre-treatment tumor specimens were
analyzed for p27, ki-67, RB and p-RB expression by
I H C .A ss h o w ni nT a b l e3, three patients had low p27
expression and two had high Ki-67 expression. Of four
patients who had sufficient tumor specimens for the
analyses of RB and pRB expression, two had no RB
expression and none had pRB expression. Of note, except
for one patient who did not have sufficient tumor
specimen for the assessment of RB and pRB expression,
all other six patients had at least one abnormal expression
of these cell cycle markers.
Buccal mucosa samples were assayed for p27 expression
by Western blot. No p27 expression was detected in these
samples. Only two of the seven serum samples had
sufficient tumor-shed serum DNA for assessing the meth-
ylation status of p16 promoter: patient 002 had methylated
p16 (RB IHC 60% positive) and patient 004 had unmethy-
lated p16 expression (RB IHC zero; data not shown). These
data are consistent with the previous report that abnormal-
ities of p16 and RB genes, both constituents of the G1
checkpoint pathway, are mutually exclusive in clinical
Table 3 Summary of correlative studies
Patient no. IHC IL-6 level (pg/mL) by ELISA
(N=7) p27 Ki-67 RB p-RB Pre-treatment Pre-second treatment At disease progression
UCD-001 30% 30% 30% 0 1.8 – 12.5
UCD-002 0 50% 60% 0 110.5 328.7 213.2
UCD-003 90% 60% –– 0 0.3 10.9
UCD-004 80% 35% 0 0 6.3 7.8 16.7
UCD-005 90% 40% –– – – –
UCD-006 100% 90% –– 2.6 5.0 6.0
UCD-007 0 10% 0 0 3.7 13.5 7.8
IHC immunohistochemistry stain. ELISA Enzyme-Linked Immunosorbent Assay
The reported normal value for IL-6 was 4.3 pg/mL
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that modulates gene expression in a number of target cell
types, including melanoma cells. We observed that plasma
IL-6 levels by ELISA were elevated by at least two folds in
post-treatment samples compared to the pre-treatment
samples, reflecting the progression of disease. Since no
objective response was observed in this study, no statistical
correlation could be performed.
Discussion
Identification of genetic abnormalities in various compo-
nents of signaling pathways involved in the initiation and
progression of melanoma has provided potential new
therapeutic targets. It is well known that cell cycle
dysregulation, such as the control of G1 phase progression,
contributes to the progression and therapeutic resistance of
malignant tumors, including metastatic melanoma. Thus,
cell cycle inhibitors have since been developed as possible
anti-cancer agents. UCN-01 was one of the first cell cycle
inhibitors evaluated in the clinical trials [23, 25, 26]. It was
thought to exert its antitumor effect by through several
mechanisms, such as inhibition of PKC and CDKs and up-
regulation of endogenous CDK inhibitors p21 and p27.
These effects have been associated with loss in G1 CDK
activity and RB dephosphorylation [8]. In this study, we
evaluated the clinical efficacy of UCN-01 in refractory,
metastatic melanoma and found insufficient activity to
warrant further study.
Since no clinical activity was observed, appropriate
correlative studies could not be pursued. However, analyses
on limited pre-treatment samples confirmed that genetic
abnormalities in key cell cycle components, such as low
level of p27, RB or pRB expression, high Ki-67 expression,
methylation of p16 promoter, are common in metastatic
melanoma despite expected variation in individual patients.
Consistent with a previous report that plasma IL-6 level is
significantly higher in melanoma patients compared to
those of healthy controls [29, 30], we found that elevation
of plasma IL-6 level is associated with disease progression,
supporting that IL-6 might be used as a surrogate biomarker
for disease progression and a valid target for the treatment
of advanced melanoma.
Althoughourtrialfailedtodemonstratesingleagentactivity
ofUCN-01inmetastaticmelanoma,itdoesnotprohibitfurther
clinical evaluation of agents targeting cell cycle dysregulation
[31, 32], either as a single agent or in combination with other
therapeutics. Recent breakthroughs in targeting BRAF muta-
tion and breaking down the barriers to tumor tolerance/
immunity by an antibody against cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4) hold great promise to improve
the treatment for this deadly disease [7, 33].
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